[
    [
        {
            "time": "2017-03-01",
            "original_text": "复星医药：郭广昌辞去董事等职务 2017年净利润31.24亿元",
            "features": {
                "keywords": [
                    "郭广昌",
                    "辞职",
                    "复星医药",
                    "净利润"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：郭广昌辞去董事等职务 2017年净利润31.24亿元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "医药股再度爆发 盘龙药业、九典制药5天4涨停",
            "features": {
                "keywords": [
                    "医药股",
                    "盘龙药业",
                    "九典制药",
                    "涨停"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药股再度爆发 盘龙药业、九典制药5天4涨停",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-15",
            "original_text": "创新药企业IPO地点如何选择？全方位剖析资本市场特点与行业特性",
            "features": {
                "keywords": [
                    "创新药",
                    "IPO",
                    "资本市场"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "创新药企业IPO地点如何选择？全方位剖析资本市场特点与行业特性",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "10万亿潜力的大健康产业中，哪些上市公司最会赚钱?先看这46家",
            "features": {
                "keywords": [
                    "大健康",
                    "上市公司",
                    "赚钱"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "10万亿潜力的大健康产业中，哪些上市公司最会赚钱?先看这46家",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-07-05",
            "original_text": "[买入评级]恒瑞医药(600276)点评：重磅麻醉药申请上市 创新药进入持续兑现期",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "麻醉药",
                    "创新药",
                    "买入评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]恒瑞医药(600276)点评：重磅麻醉药申请上市 创新药进入持续兑现期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-10",
            "original_text": "[增持评级]医药生物行业周报：深化审评审批改革卓有成效 资本助力创新发展",
            "features": {
                "keywords": [
                    "医药生物",
                    "审评审批",
                    "资本",
                    "增持评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级]医药生物行业周报：深化审评审批改革卓有成效 资本助力创新发展",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-09-15",
            "original_text": "揭秘涨停板：20股封涨停板！军工航天掀涨停潮",
            "features": {
                "keywords": [
                    "涨停板",
                    "军工航天"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "军工",
                    "航天"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "揭秘涨停板：20股封涨停板！军工航天掀涨停潮",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-20",
            "original_text": "医药生物板块一枝独秀 机构关注细分龙头和绩优股(名单)",
            "features": {
                "keywords": [
                    "医药生物",
                    "细分龙头",
                    "绩优股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物板块一枝独秀 机构关注细分龙头和绩优股(名单)",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-25",
            "original_text": "申万宏源：2018医药生物行业或有大行情开启",
            "features": {
                "keywords": [
                    "申万宏源",
                    "医药生物",
                    "大行情"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "申万宏源：2018医药生物行业或有大行情开启",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-12-01",
            "original_text": "港股异动︱医药界“华为”的药明康德周二上会 药明生物(02269)逆势涨2%",
            "features": {
                "keywords": [
                    "药明康德",
                    "药明生物",
                    "港股",
                    "上会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股异动︱医药界“华为”的药明康德周二上会 药明生物(02269)逆势涨2%",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]